CN107789621A - 一种治疗头痛的药物及其配制方法 - Google Patents

一种治疗头痛的药物及其配制方法 Download PDF

Info

Publication number
CN107789621A
CN107789621A CN201711345976.2A CN201711345976A CN107789621A CN 107789621 A CN107789621 A CN 107789621A CN 201711345976 A CN201711345976 A CN 201711345976A CN 107789621 A CN107789621 A CN 107789621A
Authority
CN
China
Prior art keywords
medicine
injection thing
treating headache
dexamethasone
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201711345976.2A
Other languages
English (en)
Inventor
李明山
李传志
陈秀芳
杨丹杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuyang City Balance Medical Health Apparatus Co Ltd
Original Assignee
Fuyang City Balance Medical Health Apparatus Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuyang City Balance Medical Health Apparatus Co Ltd filed Critical Fuyang City Balance Medical Health Apparatus Co Ltd
Priority to CN201711345976.2A priority Critical patent/CN107789621A/zh
Publication of CN107789621A publication Critical patent/CN107789621A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21001—Chymotrypsin (3.4.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开了一种治疗头痛的药物及其配制方法，其主要是由灯盏花素、安基比林、糜蛋白酶按一定比例配制而成，本发明药物具有调节骨内外压力平衡的作用，用于治疗头痛疗效快，治愈率高。

Description

一种治疗头痛的药物及其配制方法
技术领域
本发明涉及一种药物，尤其是一种治疗头痛的药物。
背景技术
头痛是一种临床常见的症状，可由多种原因引起，近期研究发现，骨减压对治疗头痛有效，头痛患者因受外界感染后全身发热，血流增加，造成骨内压增高，又因骨膜的屏障，使内外形成压力差，故而导致头痛。
发明内容
本发明的目的就是提供一种骨减压的药物。
本发明的药物包括局注药物及再注药物。
局注药物由利多卡因、地塞米松、维生素B1组成，再注药物由灯盏花素、安基比林、头孢哌酮、糜蛋白酶组成，选用利多卡因（Lidocaine），主要作用于浦肯野纤维和心室肌，抑制Na+内流而降低心肌自律性，促进心肌细胞内K+外流而引起超极化，消除折返激动，抑制心室应激性，提高心室颤动阈值。但对心房及窦房结作用很轻；在治疗剂量时，对心肌细胞的电活动具有抗室性心律失常作用，但对房室传导和心肌的收缩无明显影响；血药浓度进一步升高，可引起心脏传导速度减慢，房室传导阻滞，抑制心肌收缩力和使心排血量下降，主要用于阻滞麻醉及硬膜外麻醉。也用于室性心律失常，如室性心动过速及频发室性早搏。地塞米松（Dexamethasone，简称DXMS），地塞米松是一种人工合成的皮质类固醇，可用于治疗多种症状，包含风湿性疾病，某些皮肤病、严重过敏、哮喘、慢性阻塞性肺病、义膜性喉炎、脑水肿，也可能与抗生素合并用于结核病患者。地塞米松是糖皮质类激素。其衍生物有氢化可地松、泼尼松等，其药理作用主要是抗炎、抗毒、抗过敏、抗风湿，临床使用较广泛。极易自消化道吸收，其血浆T1/2为190分钟，组织T1/2为3日，肌注地塞米松磷酸钠或地塞米松醋酸酯后分别于l小时和8小时达血药浓度峰值。该品血浆蛋白结合率较其他皮质激素类药物为低.该品0.75mg的抗炎活性相当于5mg泼尼松龙。肾上腺皮质激素类药，抗炎、抗过敏和抗毒作用较泼尼松更强，水钠潴留和促进排钾作用很轻，可肌注或静滴对垂体-肾上腺抑制作用较强。1.抗炎作用：可减轻和防止组织对炎症的反应，从而减轻炎症的表现。激素抑制炎症细胞，包括巨噬细胞和白细胞在炎症部位的集聚，并抑制吞噬作用、溶酶体酶的释放以及炎症化学中介物的合成和释放。2.免疫抑制作用：包括防止或抑制细胞介导的免疫反应，延迟性的过敏反应，减少T淋巴细胞、单核细胞、嗜酸性细胞的数目，降低免疫球蛋白与细胞表面受体的结合能力，并抑制白介素的合成与释放，从而降低T淋巴细胞向淋巴母细胞转化，并减轻原发免疫反应的扩展。可降低免疫复合物通过基底膜，并能减少补体成份及免疫球蛋白的浓度。维生素B1，维生素B1又称硫胺素或抗神经炎维生素或抗脚气病维生素，为白色晶体，在有氧化剂存在时容易被氧化产生脱氢硫胺素，后者在有紫外光照射时呈现蓝色荧光。由嘧啶环和噻唑环通过亚甲基结合而成的一种B族维生素。为白色结晶或结晶性粉末；有微弱的特臭，味苦，有引湿性，露置在空气中，易吸收水分。在碱性溶液中容易分解变质。酸碱度在3.5时可耐100℃高温，酸碱大于5时易失效。遇光和热效价下降。故应置于遮光，凉处保存，不宜久贮。在酸性溶液中很稳定，在碱性溶液中不稳定，易被氧化和受热破坏。还原性物质亚硫酸盐、二氧化硫等能使维生素B1失活。作用用途：促进成长；帮助消化，特别是碳水化合物的消化；改善精神状况；维持神经组织、肌肉、心脏活动的正常；减轻晕机、晕船；可缓解有关牙科手术后的痛苦；有助于对带状疱疹（herpes zoster）的治疗。灯盏花素，为中药提取制剂，其剂型有片剂、注射剂、滴丸剂等。具有扩张脑血管，抗血凝的作用。临床上用于治疗脑供血不足、脑出血所致后遗症、高粘脂血症、脑血栓、冠心病、心绞痛等疾病。灯盏花素具有扩张脑血管的作用，能降低脑血管阻力，增加脑血流量，改善微循环，并有对抗血小板聚集作用。故可用于治疗缺血性脑血管疾病，如脑血栓形成，脑栓塞、脑溢血等所致后遗症瘫痪病人，具有较好疗效，对病程在6个月以内的疗效比6个月以上者好。安基比林（aminophenazone），化学名为1-苯基-2,3-二甲基-4-二甲氨基吡唑酮，白色或几乎白色的结晶性粉末；无臭，味微苦；遇光可变质；水溶液显碱性反应，用于缓解感冒、上呼吸道感染引起发热、头痛等症状，亦可用于神经痛、风湿痛、牙痛。头孢哌酮（Cefoperazone sodium）头孢哌酮为第三代头孢菌素，对大肠埃希菌、克雷白菌属、变形杆菌属、伤寒沙门菌、志贺菌属、枸橼酸杆菌属等肠杆菌科细菌和铜绿假单胞菌有良好抗菌作用，对产气肠杆菌、阴沟肠杆菌、鼠伤寒杆菌和不动杆菌属等的作用较差。流感嗜血杆菌、淋病奈瑟菌和脑膜炎奈瑟菌对本品高度敏感。本品对各组链球菌、肺炎球菌亦有良好作用，对葡萄球菌（甲氧西林敏感株）仅具中度作用，肠球菌属耐药。头孢哌酮对多数革兰阳性厌氧菌和某些革兰阴性厌氧菌有良好作用，脆弱拟杆菌对本品耐药。在脑膜发炎时，可进入脑脊液，用于各种敏感菌所致的呼吸道、泌尿道、腹膜、胸膜、皮肤和软组织、骨和关节、五官等部位的感染，还可用于败血症和脑膜炎等。糜蛋白酶（Chymotrypsin）系蛋白水解酶，尚有脂酶作用，使某些脂水解。因此可消化脓液、积血、坏死组织，起创面净化、消炎、消肿作用。主要用于创伤或手术后创伤愈合、抗炎及防止局部水肿、积血、扭伤血肿、乳房手术后水肿、中耳炎、鼻炎、角膜溃疡、泪道疾病、眼外伤、眼睑水肿、出血和玻璃体积血、慢性支气管炎、支气管扩张、肺脓肿以及毒蛇咬伤等。
具体实施方式
本发明药物包括局注药物及再注药物，其中各组分原料药的用量也是发明人经过大量的摸索总结取得的。
局注药物的用量为：利多卡因5ml、地塞米松1ml、维生素B1 0.1g。
再注药物的用量为：灯盏花素0.1ml、安基比林0.1ml、头孢哌酮0.1ml、糜蛋白酶0.1ml。
使用方法：
1、用注射器抽取利多卡因、地塞米松、维生素B1混合液中的0.5ml为麻醉剂，取太阳穴，将麻醉剂注入太阳穴中实施麻醉；
2、退去麻醉针，用负压吸引罐盖住太阳穴位负压0.1kp抽吸3分钟；
3、用穿刺针抽取灯盏花素、安基比林、头孢哌酮、糜蛋白酶混合后作为治疗剂，延太阳穴位刺入至骨板夹层的骨质部注入治疗剂，退出穿刺针，用无菌创可贴封贴针眼。
本发明将灯盏花素、安基比林、头孢哌酮、糜蛋白酶组合，使其功效产生协同作用，从而能够调节骨内外的压力平衡，达到治疗头痛的效果。
下面结合试验例进一步阐述本发明药物的有益效果。
测试头痛患者46人，用上述方法用药，其中31人一侧用药即愈，12人再由另一侧太阳穴位用药后痊愈，3人效果不明显，总有效率为93.47%。

Claims (2)

1.一种治疗头痛的药物，其特征在于：它包括局注药物及再注药物，其中：局注药物的用量为：利多卡因5ml、地塞米松1ml、维生素B1 0.1g；再注药物的用量为：灯盏花素0.1ml、安基比林0.1ml、头孢哌酮0.1ml、糜蛋白酶0.1ml。
2.一种治疗头痛药物的使用方法，其特征在于：它包括下列步骤：
（1）用注射器抽取利多卡因、地塞米松、维生素B1混合液中的0.5ml为麻醉剂，取太阳穴，将麻醉剂注入太阳穴中实施麻醉；
（2）退去麻醉针，用负压吸引罐盖住太阳穴位负压0.1kp抽吸3分钟；
（3）用穿刺针抽取灯盏花素、安基比林、头孢哌酮、糜蛋白酶混合后作为治疗剂，延太阳穴位刺入至骨板夹层的骨质部注入治疗剂，退出穿刺针，用无菌创可贴封贴针眼。
CN201711345976.2A 2017-12-15 2017-12-15 一种治疗头痛的药物及其配制方法 Withdrawn CN107789621A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711345976.2A CN107789621A (zh) 2017-12-15 2017-12-15 一种治疗头痛的药物及其配制方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711345976.2A CN107789621A (zh) 2017-12-15 2017-12-15 一种治疗头痛的药物及其配制方法

Publications (1)

Publication Number Publication Date
CN107789621A true CN107789621A (zh) 2018-03-13

Family

ID=61537775

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711345976.2A Withdrawn CN107789621A (zh) 2017-12-15 2017-12-15 一种治疗头痛的药物及其配制方法

Country Status (1)

Country Link
CN (1) CN107789621A (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1765388A (zh) * 2004-10-25 2006-05-03 刘忠山 一种速效广谱复方止痛制剂
CN1806808A (zh) * 2005-01-20 2006-07-26 马晶 灯盏花素口腔崩解片及其制备方法
CN103845530A (zh) * 2012-12-06 2014-06-11 鲜丹科 脑热瘀通
CN105163718A (zh) * 2013-05-03 2015-12-16 托马斯·M·克鲁斯 通过耳麻醉脑神经治疗疾病的方法
CN106943340A (zh) * 2017-04-28 2017-07-14 北京茗泽中和药物研究有限公司 一种盐酸利多卡因凝胶

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1765388A (zh) * 2004-10-25 2006-05-03 刘忠山 一种速效广谱复方止痛制剂
CN1806808A (zh) * 2005-01-20 2006-07-26 马晶 灯盏花素口腔崩解片及其制备方法
CN103845530A (zh) * 2012-12-06 2014-06-11 鲜丹科 脑热瘀通
CN105163718A (zh) * 2013-05-03 2015-12-16 托马斯·M·克鲁斯 通过耳麻醉脑神经治疗疾病的方法
CN106943340A (zh) * 2017-04-28 2017-07-14 北京茗泽中和药物研究有限公司 一种盐酸利多卡因凝胶

Similar Documents

Publication Publication Date Title
US6440949B1 (en) Method for promoting the growth of gram-positive bacilli and increasing the acidity in vagina
AU2014249534A1 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
CN105163806A (zh) 左西替利嗪和孟鲁司特在治疗过敏反应中的用途
US11357814B2 (en) Application of Sarcococca vagans, Chinese medicinal ointment for treating skin disease, preparation method and application thereof
JP2008255089A (ja) 上皮改善剤
US4049798A (en) Method for the treatment of Herpes Simplex
CN101455748B (zh) 一种消炎生肌药及其制备方法
CN116870159A (zh) 一种用于水痘和带状疱疹皮肤病的外用软膏剂及制备方法
CN107789621A (zh) 一种治疗头痛的药物及其配制方法
US12059440B2 (en) Preparation and application of grain worm for treating diabetes
Gordon et al. Present status of corticotropin (ACTH), cortisone, and hydrocortisone in ophthalmology
JP5456802B2 (ja) 細胞遊走促進剤及び創傷治療用の経皮吸収剤
JPH05262654A (ja) 慢性疲労症候群治療剤
Brown Therapeutic experiences with corneal ulcer due to Bacillus pyocyaneus
CN111150738A (zh) 一种治疗皮肤病的外用药物
Mabry Intranasal steroids in rhinology: the changing role of intraturbinal injection
CN101768156A (zh) 匹多莫德精氨酸盐及其制剂
Becker Medical treatment of sinusitis
CN108114090A (zh) 一种治疗痔疮和烧烫伤的中药组合物
Reid Reiter's syndrome and cortisone
CN101978968B (zh) 一种治疗中耳炎的药物
CN105477015A (zh) 一种用于肛瘘术后的外用中药洗剂及其制备方法
Banyai Topical application of codliver oil in tuberculosis: a preliminary report
TURNBULL et al. SINUSITIS AND INFECTIONS SECONDARY TO THE COMMON COLD: TREATMENT WITH STABILIZED AQUEOUS SOLUTION OF SULFATHIAZOLE SODIUM WITH DESOXYEPHEDRINE HYDROCHLORIDE
Bywaters Aspects of Steroid Therapy: The Present Status of Steroid Treatment in Rheumatoid Arthritis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20180313